Challenge - High quality translational research
• New targeted therapies require different clinical
trials
– New therapies may be highly TUMOR or PATIENT
specific –
need biomarkers
– Single attributes (eg hypoxia) or single molecules
(EGFR) are targets
– Benefit limited to specific, perhaps small patient
populations